Benitec Biopharma (BNTC) AI Stock Analysis

• Market Cap: $363.13M
• Dividend Yield: N/A
• Average Volume (3M): 127.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: 80.95%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 34,354,336
• 10 Day Avg. Volume: 168,193
• 30 Day Avg. Volume: 127,863
• PEG Ratio: 0.18
• Price to Book (P/B): 4.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.95
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 168.28
• Enterprise Value/Gross Profit: -1.42K
• Enterprise Value/Ebitda: -1.82
• 1Y Price Target: $32.00
• Price Target Upside: 200.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $11.50 ▲(8.08% Upside)
• Action: Reiterated Date: 02/14/26
• Date: Action: Reiterated 02/14/26

The score is held back primarily by weak financial performance (very small revenue base, sizable losses, and ongoing cash burn), despite a strong low-leverage balance sheet. Technicals add additional pressure given the downtrend and negative momentum, while valuation is constrained by a negative P/E and no dividend support.

Positive Factors

Balance Sheet Strength

Very low leverage provides durable financial flexibility for a clinical-stage biotech. With minimal debt relative to equity, management can fund trials, engage regulators, and pursue partnerships without heavy interest burdens or restrictive covenants, extending runway versus leveraged peers.

Promising Clinical Efficacy and Regulatory Progress

Consistent, durable BB-301 efficacy (including 24-month follow-up and 100% Cohort 1 responder rate) plus FDA Fast Track materially de-risks development. This supports a clearer pivotal path, strengthens IP and first-mover potential in OPMD, and improves odds of eventual commercialization.

Experienced Board Addition

Adding Dr. Sharon Mates brings proven biotech leadership and exit experience to governance. Her operational and M&A background can improve clinical-to-commercial planning, regulatory strategy and investor credibility—factors that sustainably increase execution probability for pivotal programs.

Negative Factors

Minimal Revenue and Large Losses

Revenue is negligible while net losses are substantial and growing, reflecting pre-revenue clinical status. Without commercialization, negative margins will persist, pressuring returns and requiring continued external funding until regulatory approval or partnering creates sustainable revenue streams.

Ongoing Negative Cash Flow

Sustained negative operating and free cash flow indicate regular cash burn to support trials. Even with some improvement versus prior periods, continued outflows erode cash reserves over time and limit strategic optionality absent financing, potentially forcing trade-offs in development pacing.

Reliance on Equity Financings

The company has used public offerings and a $200M shelf to fund operations, showing dependence on equity markets. Persistent financing needs increase dilution risk and can constrain long-term shareholder value, while also exposing program timing to capital-market cycles and investor appetite.

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

How the Company Makes Money

Benitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary

Balance sheet strength (very low debt vs. equity) provides financial flexibility, but this is offset by very weak operating fundamentals: minimal TTM revenue, large and expanding net losses, and continued negative operating/free cash flow indicating ongoing cash burn.

Income Statement

TTM (Trailing-Twelve-Months) revenue remains very small ($0.6M) and profitability is deeply negative, with a large net loss (about $50.9M) and extremely weak margins. While this is not unusual for early-stage biotech, losses have expanded versus the last annual period (net loss ~$37.9M in 2025), indicating rising spend without a meaningful revenue base yet.

Balance Sheet

The balance sheet is a relative strength: leverage is very low in TTM (Trailing-Twelve-Months) with total debt of about $1.0M against ~$187.4M of equity, leaving ample financial flexibility. The key weakness is continued negative returns on equity driven by ongoing losses, so the strong capital position is being consumed over time if profitability does not improve.

Cash Flow

Cash generation is weak, with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both around -$18.7M to -$18.8M, reflecting a business that is still funding operations through its balance sheet. Free cash flow also deteriorated versus the prior period (negative growth), although cash burn is lower than the 2025 annual operating cash outflow (~-$23.6M), suggesting some improvement in cash discipline.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	556.00K	0.00	0.00	75.00K	73.00K	59.00K
Gross Profit	-66.00K	-396.00K	-343.00K	-306.00K	64.00K	-64.00K
EBITDA	-51.33M	-41.70M	-21.41M	-19.15M	-17.85M	-13.45M
Net Income	-46.30M	-37.92M	-21.75M	-19.56M	-18.21M	-13.88M
Balance Sheet
Total Assets	190.68M	99.59M	52.21M	4.46M	5.97M	21.38M
Cash, Cash Equivalents and Short-Term Investments	188.79M	97.74M	50.87M	2.48M	4.06M	19.77M
Total Debt	987.00K	849.00K	284.00K	559.00K	811.00K	213.00K
Total Liabilities	3.32M	2.30M	4.96M	4.26M	3.09M	1.37M
Stockholders Equity	187.36M	97.30M	47.25M	202.00K	2.88M	20.01M
Cash Flow
Free Cash Flow	-18.76M	-23.61M	-19.58M	-18.01M	-15.91M	-13.05M
Operating Cash Flow	-18.74M	-23.59M	-19.40M	-18.01M	-15.90M	-12.83M
Investing Cash Flow	-17.47K	-18.00K	-179.00K	-1.00K	-13.00K	-221.00K
Financing Cash Flow	130.92M	70.48M	68.03M	16.02M	0.00	22.52M

Benitec Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 10.64 is below the 20-day moving average (MA) of 11.73, below the 50-day MA of 12.11, and below the 200-day MA of 13.28, indicating a bearish trend. The MACD of -0.47 indicates Positive momentum. The RSI at 37.97 is Neutral, neither overbought nor oversold. The STOCH value of 33.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.

Benitec Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCKT	52 Neutral	$373.37M	-1.66	-74.88%	―	―	18.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNTC	49 Neutral	$363.13M	-11.66	-29.59%	―	―	80.95%
ASMB	49 Neutral	$456.96M	-5.41	-36.94%	―	31.30%	32.79%
FDMT	47 Neutral	$467.74M	-2.33	-45.38%	―	―	―
TVRD	46 Neutral	$33.77M	-0.36	-97.61%	―	-53.67%	86.75%
AURA	42 Neutral	$320.06M	-2.78	-64.26%	―	―	-11.41%

Benitec Biopharma Corporate Events

Benitec Biopharma Concludes 2025 Annual Stockholders Meeting

On December 1, 2025, Benitec Biopharma Inc. held its virtual 2025 Annual Meeting of Stockholders, where 85.06% of the company’s shares were represented. The meeting resulted in the election of directors, ratification of an independent accounting firm, and approval of executive compensation, with all proposals receiving the necessary votes for approval.

The most recent analyst rating on (BNTC) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.